Asthma and COPD Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

The Asthma and COPD Drugs Market is segmented by Drug Class, Indication, and Geography.

Market Snapshot

Asthma and COPD Drugs Market_Image 1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

4.2%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The asthma and COPD drugs market is expected to witness a CAGR of 4.2% during the forecast period. Certain factors that are driving the market growth include increase in incidence and prevalence of asthma and COPD, technological advancements, and growing geriatric population.

  • The global population is aging rapidly, owing to reduced birth rates and increasing life expectancy. According to the US Census Bureau’s Statistics, as of 2017, the total number of people aged between 65 years and older, exceeded 50 million. According to the United Nations, during the period of 2015-2030, the number of older persons aged 60 years or over, worldwide, is projected to grow by 56% (from 901 million to more than 1.4 billion).
  • Moreover, economic and social commission for Asia and the Pacific (ESCAP), reports that the geriatric population in Asia-Pacific was around 617.1 million in 2015, accounting for more than half of the world’s total elderly population. It is estimated that, by 2050, Asia-Pacific may account for almost two-thirds of the world’s geriatric population. Hence, owing to the fact that asthma is a widely prevalent disease found in people over age 65, the growing geriatric population is expected to drive the market growth over the forecast period.

Scope of the Report

Asthma is a chronic respiratory disease, which blocks the airways of the lung because of mucus production, inflammation, and tightening of muscles. Similarly, chronic obstructive pulmonary disease (COPD) is caused by the blockade in the airways, further resulting in difficulty in breathing. Asthma and COPD drugs are the drugs which are used to treat these aforementioned respiratory diseases.

By Drug Class
Bronchodilators
Short Acting Beta-2 Agonists
Long Acting Beta-2 Agonists
Anti-cholinergic Agents
Anti-inflammatory Drugs
Oral and Inhaled Corticosteroids
Anti-leukotrienes
Phosphodiesterase Type-4 Inhibitors
Other Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
By Indication
Asthma
Chronic Obstructive Pulmonary Disease
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Asthma is Expected to Hold the Largest Market Share in the Indication Type

According to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, approximately 8.3% of children in the United States were found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively. Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.

Asthma and COPD Drugs Market_Image 2

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the AAAI, in 2012, the median annual medical cost of asthma was USD 983 in the United States. This ranged from an average low of USD 833 in Arizona to an average high of USD 1,121 in Michigan. In addition, there were 3,615 asthma-related deaths in 2015. Children under 18 years old made up 219 of those deaths. Asthma prevalence was the highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey. Workers in the educational services industry reported the second-highest rate (8.2%) of asthma prevalence. Hence, the growing prevalence of asthma is expected to contribute to the significant market share of the North American market over the forecast period.

Asthma and COPD Drugs Market_Image 3

To understand geography trends, Download Sample Report

Competitive Landscape

The asthma and COPD drugs market is highly competitive and consists of few major players. Companies, like Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Grifols, Novartis AG, Pfizer, Roche Holding AG, and Teva Pharmaceutical, among others, hold the substantial market share in the asthma and COPD drugs market.

Major Players

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. GlaxoSmithKline
  4. Grifols
  5. Merck & Co.

* Complete list of players covered available in the table of contents below

Asthma and COPD Drugs Market_Image 4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Incidence and Prevalence of Asthma and COPD

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Growing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations for the Product Approval

      2. 4.3.2 Side Effects Associated with Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Bronchodilators

        1. 5.1.1.1 Short Acting Beta-2 Agonists

        2. 5.1.1.2 Long Acting Beta-2 Agonists

        3. 5.1.1.3 Anti-cholinergic Agents

      2. 5.1.2 Anti-inflammatory Drugs

        1. 5.1.2.1 Oral and Inhaled Corticosteroids

        2. 5.1.2.2 Anti-leukotrienes

        3. 5.1.2.3 Phosphodiesterase Type-4 Inhibitors

        4. 5.1.2.4 Other Anti-inflammatory Drugs

      3. 5.1.3 Monoclonal Antibodies

      4. 5.1.4 Combination Drugs

    2. 5.2 By Indication

      1. 5.2.1 Asthma

      2. 5.2.2 Chronic Obstructive Pulmonary Disease

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Grifols

      5. 6.1.5 Merck & Co.

      6. 6.1.6 Pfizer

      7. 6.1.7 Roche Holding AG

      8. 6.1.8 Sumitomo Dainippon Pharma

      9. 6.1.9 Teva Pharmaceutical

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information